Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent expiration date of guselkumab?
Can i take anti histamine with statin?
Drugpatentwatch trametinib?
Is clarinex off patent?
When is xarelto's patent set to expire roughly?

Demerol meperidine market share?

See the DrugPatentWatch profile for Demerol

Who has the biggest share in the meperidine (Demerol) market?

The provided information does not include any market-share breakdown for meperidine (Demerol), such as which manufacturers hold the largest sales share or how share is measured (units vs. revenue, by country vs. global). Without that data, there isn’t a factual basis to name “top players” or give percentage shares.

What does “market share” mean for meperidine, and why it’s hard to answer without the dataset?

For older, tightly regulated generics like meperidine, market-share figures can vary a lot depending on:
- Geography (U.S. vs. global)
- Metric (units sold, prescriptions, or wholesale revenue)
- Time period (year/quarter)
- Formulation and dosage strength included
- Whether sales through specific channels (e.g., hospitals vs. retail) are counted

Because none of those inputs are included here, any specific number would be guesswork.

If you meant “U.S. market share,” what source would typically be used?

To answer “Demerol (meperidine) market share” credibly, you’d usually need one of these types of sources:
- Prescription audit data (e.g., claims/prescriptions by brand or NDC)
- Wholesale/dispensing datasets used by market research firms
- Industry reports that break out top manufacturers and their shares
- Regulatory or purchasing databases (more common for procurement than for true market share)

Can you share what country and timeframe you want?

If you tell me:
1) country (e.g., U.S., Canada, EU),
2) year or date range, and
3) whether you want share by manufacturer, brand/NDC, or total prescriptions,

I can narrow the request to the right format and help you interpret the market-share numbers you find.

What you can do next to get the exact numbers

If you already have a report/table, paste it (even a screenshot converted to text). I can extract:
- each company’s share,
- the top holders,
- how the shares sum up,
- and any notes about data definitions.

Sources: none provided in the prompt.



Other Questions About Demerol :

meperidine (demerol) Does demerol cause more hallucinations than fentanyl? Do they still make demerol? Demerol generic? Us demerol meperidine market? Is demerol still available? Is demerol still used?

AI-Drug Label Prescribing Information Alignment Report

78
78%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI response aligns well with the FDA label themes for DEMEROL’s serious/life-threatening risks (opioid addiction/overdose, respiratory depression, CNS depressant co-use incl. alcohol, MAOI contraindication, CYP3A4 inhibitor effects, serotonin syndrome, neonatal withdrawal). However, the evaluation is limited by missing verbatim boxed-warning text in the prompt and does not address pediatric safety or broader pregnancy/labor-related warnings that may exist elsewhere in the label.

Category Scores

Contraindications
85
Good
Warnings
80
Good
DrugInteractions
82
Good
SpecificPopulations
70
Partial

Accurate Statements

DEMEROL warning themes include opioid addiction/abuse/misuse and increased overdose/death risk with higher doses.
Supported by label section 5.1 (as provided in the prompt).
DEMEROL warning themes include serious/life-threatening/fatal respiratory depression, especially during initiation or after dose increases; major hazards include respiratory depression and respiratory arrest.
Supported by label sections 5.2 and 6 (as provided in the prompt).
Concomitant use of opioids with benzodiazepines or other CNS depressants (including alcohol) may cause profound sedation, respiratory depression, coma, and death, and concomitant prescribing should be reserved for inadequate alternatives with monitoring.
Supported by label section 5.3 and 7 (as provided in the prompt).
MAOIs: concomitant use is contraindicated and can result in coma and severe respiratory depression; use within last 14 days is contraindicated.
Supported by label sections 5.6, 4, and 7 (as provided in the prompt).
CYP3A4 inhibitor co-use may increase meperidine plasma concentrations and could increase or prolong adverse reactions and cause potentially fatal respiratory depression.
Supported by label sections 5.5 and 7 (as provided in the prompt).
Serotonergic co-use may cause potentially life-threatening serotonin syndrome; DEMEROL should be discontinued if serotonin syndrome is suspected.
Supported by label section 5.8 (as provided in the prompt).
Extended opioid use during pregnancy can cause neonatal opioid withdrawal syndrome that may be life-threatening if not recognized and treated.
Supported by label section 5.4 (as provided in the prompt).

Unsupported Statements

The boxed-style warning is fully and precisely aligned with FDA-required boxed-warning wording.
The prompt provides section excerpts and themes, but not the complete boxed-warning text verbatim; the AI conclusion about exact boxed-warning phrasing cannot be verified from the provided material.

Contradictions

Important Omissions

No pediatric-safety section is cited/covered in the analysis (if present in the label).
Importance: Moderate
Broader pregnancy/labor-related labeling beyond neonatal opioid withdrawal syndrome is not explicitly referenced (e.g., not cited except for 5.4).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The response’s claims track multiple serious risk themes from the provided label excerpts; it does not provide dosing or management instructions that could directly cause unsafe use. Main limitations are completeness/verification of exact boxed-warning wording and missing citations for additional populations/sections.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Incomplete verification of exact boxed-warning language and limited coverage of population-specific citations (notably pediatric, and potentially broader pregnancy/labor sections beyond 5.4).

Suggested Improvement
Include verbatim boxed-warning text (or cite the exact boxed-warning section content if available) and explicitly address any label sections relevant to pediatric and pregnancy/labor beyond neonatal withdrawal syndrome when evaluating the full boxed-warning scope.